Alzamend Neuro Inc (ALZN) Stock Score, Valuation & Financial Research

Alzamend Neuro Inc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ALZN

Alzamend Neuro Inc does not currently have a complete Wall Street Score. The stored market price is USD 1.37. These figures are a research snapshot, not a buy or sell recommendation.

What Alzamend Neuro Inc does

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Company business and revenue

Research reporting period: 2026-04-30. A research update is not a new financial filing.

How the company makes money

Alzamend Neuro is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on financing operations through the issuance of equity and debt instruments to fund the research and development of novel therapeutic drug candidates for neurological and psychiatric disorders.

Products and services

  • The company is developing two primary product candidates: AL001, an ionic cocrystal of lithium for the treatment of Alzheimer's, bipolar disorder, major depressive disorder, and PTSD; and ALZN002, an active immunotherapy product candidate for Alzheimer's disease.

Brands and product families

  • AL001 — Lead product candidate, an ionic cocrystal of lithium. Source
  • ALZN002 — Active immunotherapy product candidate. Source

Customer types

Patients with Alzheimer's disease; Patients with bipolar disorder; Patients with major depressive disorder; Patients with post-traumatic stress disorder.

Suppliers, materials and equipment

  • Contract Research Organizations — The company utilizes third-party contract research organizations to manage and conduct its clinical trials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Massachusetts General Hospital — Collaborating as a contract research organization to conduct Phase II clinical trials for AL001. Source

Business strengths to evaluate

  • Proprietary ionic cocrystal technology for AL001 Source

Business risks and research considerations

  • Requirement for additional funding to continue research and development Source
  • Clinical trial failure or delays Source

Sources: Company research source · Massachusetts General Hospital

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ALZN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.37
Market capitalization:
5.21M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -9.1M
Free cash flow:
USD -8.07M
Cash:
USD 7.59M
Total debt:
USD 0.00
EPS:
USD -2.30

What stands out

  • Free cash flow is USD -8.07M, negative for the stored period.
  • The balance sheet shows USD 7.59M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 7.59M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ALZN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ALZN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ALZN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ALZN to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ALZN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research ALZN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.